Hepatology · Herbal MedicineSafety Signalregulatorymid-term

Concerns Raised Over Hepatotoxicity of Epimedium brevicornu Maxim.

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 6:31:36 AM

Assessment confidence: 50% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The emerging safety concerns regarding hepatotoxicity associated with Epimedium brevicornu Maxim. could significantly impact its market perception and usage. Pharma strategy teams must closely monitor ongoing research and potential regulatory actions to mitigate risks and maintain consumer trust. Regulatory context from PMDA ([IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026) supports the near-term read. Assessment grounded in 24 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the safety profiles of herbal products and consider potential regulatory implications or shifts in consumer trust. The strongest clinical anchor is A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ClinicalTrials.gov), moderate corpus alignment. In Hepatology · Herbal Medicine, 7 regulatory and 5 competitive items passed relevance filtering for regulatory agencies.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from [Ad hoc announcement pursuant to Art.. The rising safety concerns may impact the market perception and usage of Epimedium brevicornu-based products, potentially affecting competitors in the herbal medicine space.

Regulatory Outlook

Regulatory risk is concentrated around [IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026 (PMDA). Moderate corpus alignment. Relevant agencies in corpus: PMDA, MHRA, FDA. Increased scrutiny from regulatory agencies may result in new guidelines or restrictions on the use of Epimedium brevicornu, impacting its approval and market availability.

Key Risks

Elevated high regulatory exposure for regulatory agencies could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If safety concerns lead to decreased consumer trust or regulatory restrictions, it could adversely affect sales and market share of Epimedium brevicornu-based products.
Upside for regulatory agencies may improve if Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain (ClinicalTrials.gov) delivers favorable follow-through.
Medical Devices · IV Administration · Safety Signal · This safety signal could impact Baxter's reputation and market share in the IV administration device sector, potentially benefiting competitors.
Upside for regulatory agencies may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Upside for regulatory agencies may improve if The effect of provenance and species on the chemical composition of Epilobium herbal tea. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor for further studies identifying toxic components and any regulatory actions regarding Epimedium brevicornu.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

[IBENTO][IBENTO]PMDA-ATC Herbal Medicine Seminar 2026
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA delivers record performance as 2025-26 Annual Report and Accounts confirms growing global influence
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Corporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Drug Competition Action Plan | Maximizing scientific and regulatory clarity with respect to complex generic drugs
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Impro
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Traditional Chinese Medicine Patch for Cancer-Related Fatigue During Radiotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Unique Pharmaceutical Laboratories Recalls Cetirizine Hydrochloride Due to Ranitidine Contamination
Humanexa Signalsmedium relevance
Moderate corpus alignment
Baxter Faces Early Alert Over Intravascular Administration Set Air Bubble Issue
Humanexa Signalsmedium relevance
Moderate corpus alignment

Screening of hepatotoxic components of Epimedium brevicornu Maxim.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The effect of provenance and species on the chemical composition of Epilobium herbal tea.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Migraine relief: Solutions from natural bioactive products of Traditional Chinese medicine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A cell-based affinity mass spectrometry strategy for the rapid discovery of active components from Chinese herbal formulae: Chai-Gui decoction as a study case.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

regulatory agencies

Commercial impact

medium

If safety concerns lead to decreased consumer trust or regulatory restrictions, it could adversely affect sales and market share of Epimedium brevicornu-based products.

Regulatory impact

high

Increased scrutiny from regulatory agencies may result in new guidelines or restrictions on the use of Epimedium brevicornu, impacting its approval and market availability.

What to watch

Monitor for further studies identifying toxic components and any regulatory actions regarding Epimedium brevicornu.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.